(MENAFN- PR Newswire) JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract
(abstract # 251) that details results from
the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and safety of
Qilu Pharmaceuticals' iparomlimab and tuvonralimab (QL1706) in cervical cancer was selected for oral presentation on 8 March, local time.
Access the abstract here: #!
Continue Reading
![image]( "image")
image
This study was led by Professor Jihong Liu from the Sun Yat-sen University Cancer Center
and Professor Hanmei Lou from the Zhejiang Cancer Hospital.
This was a multi-center, single-arm, phase II study which recruited patients with recurrent or metastatic cervical cancer unresponsive to
first-line
platinum-based
chemotherapy (with or without bevacizumab)
and without prior
immunotherapy. Participants received QL1706 at a dose of 5.0 mg/kg
once every three weeks
(Q3W).
The study involved 38 medical centers across China and
enrolled 148 patients, with a median follow-up of 11.0 months at
the data cut-off. The primary endpoint, the objective response rate (ORR), as assessed
by an
Independent Evaluation Committee (IRC), was 33.8%, meeting the prespecified criteria. The disease control rate (DCR) was 64.9% and median progression-free survival (PFS) was 5.4 months. Overall survival (OS) was not reached.
Treatment-related adverse events (TRAEs)
occurred in 104 (70.3%) subjects, with
36 (24.3%) experiencing grade ≥3 TRAEs. Anemia (4.1%)
was
the most common
TRAE. Treatment discontinuation due to TRAEs occurred in three patients (2.0%). TRAE leading to death didn't occur.
The trial indicates that QL1706 is an effective and safe therapy for patients with recurrent or metastatic cervical cancer whose disease progressed after first-line standard of care. In August 2023, the China NMPA, Center for Drug Evaluation (CDE) accepted the new drug application for QL1706, making it the first MabPair product targeting PD-1 and CTLA-4 worldwide and a potential new treatment option for patients with cervical cancer.
Photo -
Logo -
MENAFN04032024003732001241ID1107930029
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.